Trials / Completed
CompletedNCT01846104
Booster Dose (50 µg) of Recombinant Ricin Toxin Vaccine (RVEc™) in Previously Vaccinated Healthy Adults
Safety and Immunogenicity of a Booster Dose (50 µg) of Recombinant Ricin Toxin A-Chain 1-33/44-198 (rRTA 1-33/44-198) Vaccine (RVEc™) in Previously Vaccinated Healthy Adults
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- U.S. Army Medical Research and Development Command · Federal
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the safety and immunogenicity of a single 50-μg booster dose of RVEc. Subjects will be recruited from the cohort that received three 50-μg doses of RVEc in a Phase 1 trial (NCT01317667).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | 50-μg booster dose RVEc | Subjects will be recruited from the 10 subjects who received three 50-μg doses of RVEc during the Phase 1 trial. Subjects will receive a single booster dose only and will be followed for 6 months after vaccination. |
Timeline
- Start date
- 2013-04-30
- Primary completion
- 2013-06-30
- Completion
- 2013-06-30
- First posted
- 2013-05-03
- Last updated
- 2019-12-27
- Results posted
- 2016-11-21
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01846104. Inclusion in this directory is not an endorsement.